சுவிஸ் அதிகாரி கஸெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுவிஸ் அதிகாரி கஸெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுவிஸ் அதிகாரி கஸெட் Today - Breaking & Trending Today

Where Can You Go To Find Out Company Information In Switzerland? - Corporate/Commercial Law

In this article we're going to be focusing on what company information is available to the public for companies which are registered in Switzerland. ....

United Kingdom , Swiss Code , Swiss Official Gazette , Central Business Name Index , Where Can You Go To Find Out Company Information In Switzerland , Corporate Commercial Law , Contracts And Commercial Law , Corporate And Company Law , ஒன்றுபட்டது கிஂக்டம் , சுவிஸ் குறியீடு , சுவிஸ் அதிகாரி கஸெட் , பெருநிறுவன வணிகரீதியானது சட்டம் , ஒப்பந்தங்கள் மற்றும் வணிகரீதியானது சட்டம் , பெருநிறுவன மற்றும் நிறுவனம் சட்டம் ,

Coca Cola HBC AG (LSE:CCH) | RNS | Coca-Cola HBC AG

22 June 2021,

Zug, Switzerland -
21 May 2021 - The Board of Directors of Coca-Cola HBC AG ( Coca-Cola HBC ) has resolved to convene the Annual General Meeting ( AGM ) to be held on Tuesday,
22 June 2021 at
Switzerland.

As a result of the Coronavirus pandemic, the Swiss Government has issued emergency laws prohibiting physical attendance by shareholders at the AGM. Due to these restrictions, the AGM this year will be a closed meeting and shareholders will not be able to attend in person. Voting will take place exclusively through the independent proxy. The participation of shareholders is very important to Coca-Cola HBC and all shareholders are encouraged to participate in the AGM by appointing the independent proxy, according to the details set out in the notice of AGM. ....

United States , United Kingdom , City Of , Switzerland General , Alexandra Papalexopoulou , Henrique Braun , Anna Diamantopoulou , Bruno Pietracci , Zoran Bogdanovic , Schweizerisches Handelsamtsblatt , Williamw Douglas , Bryan Rudolph , Alfredo Rivera , Octavio Reyes , Anastasiosi Leventis , Charlottej Boyle , Reto Francioni , Anastassisg David , Christodoulos Leventis , Olusola Sola David Borha , London Stock Exchange , Cola Company , National Storage Mechanism , Remuneration Committee , United Kingdom Financial Conduct Authority Listing Rule , Athens Exchange ,

Compagnie Financière Tradition: Voting result of the Annual General Meeting and dividend

Compagnie Financière Tradition: Voting result of the Annual General Meeting and dividend
Voting result of the Annual General Meeting and dividend
The Annual General Meeting held on May 19, 2021 at 3.30 pm approved the proposal of the Board of Directors published in the Swiss Official Gazette of Commerce on April 28, 2021.
Further to this meeting, Compagnie Financière Tradition SA is pleased to announce the election of Mr. Alain Blanc-Brude, as a new Director.
Moreover, the dividend consists of a cash payment of a gross amount of CHF 5.00 («cash dividend») per bearer share of CFT with a nominal value of CHF 2.50 («bearer share(s)») and the distribution of one bearer share for every 75 bearer shares held («stock dividend»). ....

Kostenloser Wertpapierhandel , Patrick Combes , Alain Blanc Brude , Rohan Sant , Swiss Exchange , Annual General Meeting , Swiss Official Gazette , Compagnie Financi , Financi 232 Re , பேட்ரிக் சீப்பு , ரோஹன் சந்த் , சுவிஸ் பரிமாற்றம் , ஆண்டு ஜநரல் சந்தித்தல் , சுவிஸ் அதிகாரி கஸெட் ,

Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway

131.3
US GAAP revenue of CHF 7 million in the first quarter of 2021 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 1 million), Janssen Biotech, Inc. (CHF 3 million), Roche (CHF 2 million) and Mochida Pharmaceutical Co., Ltd (CHF 1 million) compared to a revenue of CHF 5 million in the first quarter of 2020.
US GAAP operating expenses in the first quarter of 2021 amounted to CHF 129 million (CHF 116 million in the first quarter of 2020), of which CHF 97 million relates to R&D (CHF 97 million in the first quarter of 2020) and CHF 31 million to SG&A expenses (CHF 19 million in the first quarter of 2020). ....

Switzerland General , Andrewc Weiss , Neurocrine Biosciences , Guy Braunstein , Jean Paul Clozel , Simon Jose , Jean Yves Chatelan , Company Annual , Head Of Investor Relations Corporate Communications , Janssen Biotech Inc , Janssen Pharmaceutical Companies Of Johnson , Japanese Pharmaceuticals , European Union , Clinical Development , Neurocrine Biosciences Inc , Idorsia Ltd , Day Center , Swiss Exchange , Actelion Pharmaceuticals Ltd , Mochida Pharmaceutical Co Ltd , Head Of Global Clinical Development Idorsia , Idorsia Pharmaceuticals Ltd , European Medicines Agency , Devices Agency , Medical Devices Agency , Paul Clozel ,

Idorsia announces financial results for the first quarter 2021 – substantial progress made ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Idorsia announces financial results for the first quarter 2021 – substantial progress made .
Idorsia Pharmaceuticals LtdApril 22, 2021 GMT
Allschwil, Switzerland – April 22, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2021.
Business highlights
Daridorexant new drug application (NDA) submitted to the US FDA in January 2021 and has been accepted for review
Daridorexant marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA) in March 2021
Daridorexant MAA submitted to Switzerland’s health authority, Swissmedic, in April 2021
Daridorexant Phase 3 program has concluded – supporting the chronic use of daridorexant in insomnia ....

Switzerland General , Andrewc Weiss , Neurocrine Biosciences , Guy Braunstein , Jean Paul Clozel , Simon Jose , Jean Yves Chatelan , Company Annual , Head Of Investor Relations Corporate Communications , Janssen Biotech Inc , Janssen Pharmaceutical Companies Of Johnson , Japanese Pharmaceuticals , European Union , Clinical Development , Neurocrine Biosciences Inc , Idorsia Ltd , Day Center , Swiss Exchange , Actelion Pharmaceuticals Ltd , Mochida Pharmaceutical Co Ltd , Head Of Global Clinical Development Idorsia , Idorsia Pharmaceuticals Ltd , European Medicines Agency , Devices Agency , Medical Devices Agency , Paul Clozel ,